The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.

According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

Burning Rock will add the prostate Genomic Instability Score (prGIS) algorithm to its myChoice HRD Plus assay and will develop new HRD tests on its OncoScreen Plus platform.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

Roche announced on Tuesday that it its Cobas hepatitis D test has been CE marked and the company is launching it in countries that accept the designation. The high-throughput test is intended for the ...

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

Last week, readers were most interested in a story about Roche's blood-based IGRA test for latent TB getting CE marking.

The updated test showed 80 percent sensitivity for detecting colorectal cancer overall and 18 percent sensitivity for advanced precancerous lesions.

Sapphiros will use the funding to develop its molecular diagnostic platform for biothreat and emerging infectious disease detection in point-of-care settings.